DEF: Utah Medical Products Schedules 2026 Annual Meeting

Utah Medical Products, Inc. (UTMD) has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation.

Summary

• Utah Medical Products, Inc. (UTMD) is holding its 2026 Annual Meeting of Stockholders on May 1, 2026, at 12:00 PM Mountain Time at its corporate offices in Midvale, Utah.
• The meeting agenda includes the election of two directors, ratification of Haynie & Company as the independent auditor for the fiscal year ending December 31, 2026, and an advisory vote on the company's executive compensation program.
• Stockholders of record as of March 2, 2026, are eligible to vote.
• The company's Board of Directors recommends voting FOR all three proposals.
• Key management personnel, including the CEO and Chairman Kevin L. Cornwell, hold approximately 7.2% of the outstanding shares and have indicated their intent to vote in favor of all proposals.
• The filing also provides details on executive compensation, director compensation, security ownership, and corporate governance policies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to underperformance in key financial metrics, declining stock price, and missed objectives, despite a long history of profitability and strong long-term shareholder returns.

Positives

• The company has a long history of profitability, with 39 years of positive earnings since 1986.
• Stockholder value, including share price appreciation and dividends, has grown 1,117% over the last 27 years, outpacing major indices.
• The company maintains a consistent compensation philosophy focused on pay for performance, fairness, competitive pay, effective reviews, and clear communication.
• The Board of Directors is committed to diversity, inclusion, and equity.
• Independent directors constitute 67% of the Board, meeting Nasdaq requirements.
• The company has a robust risk oversight process managed by the Board of Directors and its committees.
• The Audit Committee has established an independent whistleblower hotline.
• The company has a clawback policy for erroneously awarded compensation.
• The company has a history of repurchasing shares, which has historically offset dilution from stock options.

Negatives

• The company's stock price at the end of 2025 ($55.96) was lower than all year-end prices since 2012.
• UTMD did not achieve its beginning-of-year objectives for sales, net profits, and EPS in 2025.
• The CEO's base salary was reduced by half for the remainder of 2025.
• The CEO's annual management bonus for 2025 was 15% lower than in 2024 due to a 16% decrease in pretax/pre-MB EBT.
• Bonuses for employees generally ranged from 15% lower to the same as in 2024, with some employees experiencing a 25% reduction.
• Two Section 16(a) filing requirements were missed: Brian Koopman's Form 4 was twenty days late, and Kevin Timken's Form 3 was thirty-eight days late.
• The company's stock performance has underperformed the NASDAQ Composite and NASDAQ Medical Supplies indices over the last five years.

Risks

• The company's stock price has declined significantly from previous years.
• Failure to achieve sales, net profits, and EPS objectives in 2025 indicates potential operational or market challenges.
• The company's executive compensation is tied to financial performance, which could lead to reduced bonuses if targets are not met.
• The company operates in a consolidating marketplace, which may present competitive challenges.
• Product liability exposure is a risk that the Board of Directors oversees.

Future Outlook

The company aims to enhance long-term profitability, EBITDA, EPS growth, and return on stockholders equity by aligning management and employee interests with those of stockholders. The Board of Directors will continue to recommend proposals for director elections, auditor ratification, and executive compensation. The company plans to continue its retirement plan contributions on the same basis as in 2024 and 2025.

Management Comments

• "UTMD has always maintained an open invitation for stockholders to call management directly with questions and/or concerns."
• "The Board of Directors considers this policy highly contributory to growth in future stockholder value."
• "Management expects to recommend that additional options be awarded on an annual basis to the Companys key employees based on its belief that sharing ownership of the Company with those who help create its success is the best way to assure growth in stockholder value."

Industry Context

StockSavvy.ai notes that Utah Medical Products, Inc. operates in the medical device industry. The company's stock performance has lagged behind broader market indices like the Nasdaq Composite and its specific industry peer group over the past five years, suggesting potential challenges in market competitiveness or product innovation compared to peers.

Comparison to Industry Standards

• The company's stock performance chart shows that a $100 investment on December 31, 2020, would have grown to $79.50 by December 31, 2025, for UTMD stock. In contrast, the NASDAQ Composite Total Return would have grown to $187.10, and the NASDAQ ICB: 4537 Medical Supplies index would have grown to $68.00 over the same period.
• The company's long-term EPS growth of 12% annually and ROE of 25% are strong historical figures, but the recent decline in stock price and failure to meet 2025 objectives warrant attention.
• Executive compensation is benchmarked against similarly sized companies in the same or similar businesses, with base salaries set somewhat below competitive levels, and bonuses and stock options more highly leveraged to company success.

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors, ratification of the auditor, and advisory vote on executive compensation directly impact shareholder governance and oversight. The company's historical long-term shareholder value growth is highlighted, but recent stock price decline and missed financial targets may concern shareholders.
• Employees: Compensation programs, including bonuses and stock options, are designed to align employee interests with stockholder interests. The company provides retirement plans and group benefit plans.
• Management: Executive compensation is detailed, with a focus on performance-based bonuses and stock options. The CEO's compensation has been impacted by company performance.
• Auditors: Stockholders are asked to ratify the selection of Haynie & Company as the independent auditor for 2026. Fees for audit and tax services are disclosed.

Next Steps

• Stockholders are encouraged to submit their proxies promptly for the 2026 Annual Meeting.
• The Board of Directors will review the advisory vote results on executive compensation.
• Stockholder proposals for the 2027 Annual Meeting must be received by December 1, 2026.

Key Dates

Recommendation

While the company has a strong historical track record of profitability and long-term shareholder value creation, recent underperformance, missed financial targets, and a declining stock price suggest caution. The upcoming annual meeting addresses key governance items, but the immediate outlook based on 2025 results warrants a 'hold' position until performance trends improve.

Keywords

Utah Medical Products, UTMD, Proxy Statement, Annual Meeting, DEF 14A, Director Election, Independent Auditor, Executive Compensation, Corporate Governance, Stockholder Meeting